)
)
Machine learning combined with 3D genomics identify drug targets with boosted clinical success chances
-
Solving disease-associated non-coding variants entails identifying if they are functional, and then identifying which genes they affect
-
Nucleome platform utilises a combination of machine learning and single-base pair 3D genomics (Micro Capture-C (MCC)) to solve both problems with precision at scale
-
This identifies drug targets that are multiple times more clinically successful than industry norms, validated by historical programmes with known outcomes
